Cynata Therapeutics Limited

ASX:CYP 주식 보고서

시가총액: AU$41.6m

Cynata Therapeutics 관리

관리 기준 확인 3/4

Cynata Therapeutics' CEO is Kilian Kelly, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is A$544.83K, comprised of 71.7% salary and 28.3% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth A$142.52K. The average tenure of the management team and the board of directors is 2.2 years and 4.4 years respectively.

주요 정보

Kilian Kelly

최고 경영자

AU$544.8k

총 보상

CEO 급여 비율71.7%
CEO 임기1.3yrs
CEO 소유권0.3%
경영진 평균 재임 기간2.2yrs
이사회 평균 재임 기간4.4yrs

최근 관리 업데이트

Recent updates

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Sep 21
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

May 29
Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Feb 09
We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09
We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26
Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Dec 31
Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Aug 11
We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

CEO 보상 분석

Kilian Kelly 의 보수는 Cynata Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024AU$545kAU$391k

-AU$10m

Mar 31 2024n/an/a

-AU$12m

Dec 31 2023n/an/a

-AU$14m

Sep 30 2023n/an/a

-AU$14m

Jun 30 2023AU$413kAU$334k

-AU$14m

Mar 31 2023n/an/a

-AU$12m

Dec 31 2022n/an/a

-AU$9m

Sep 30 2022n/an/a

-AU$7m

Jun 30 2022AU$499kAU$313k

-AU$5m

Mar 31 2022n/an/a

-AU$5m

Dec 31 2021n/an/a

-AU$4m

Sep 30 2021n/an/a

-AU$6m

Jun 30 2021AU$737kAU$300k

-AU$8m

Mar 31 2021n/an/a

-AU$7m

Dec 31 2020n/an/a

-AU$6m

Sep 30 2020n/an/a

-AU$5m

Jun 30 2020AU$472kAU$300k

-AU$4m

Mar 31 2020n/an/a

-AU$6m

Dec 31 2019n/an/a

-AU$8m

Sep 30 2019n/an/a

-AU$8m

Jun 30 2019AU$449kAU$279k

-AU$8m

Mar 31 2019n/an/a

-AU$7m

Dec 31 2018n/an/a

-AU$6m

Sep 30 2018n/an/a

-AU$5m

Jun 30 2018AU$357kAU$259k

-AU$5m

보상 대 시장: Kilian's total compensation ($USD359.84K) is about average for companies of similar size in the Australian market ($USD299.27K).

보상과 수익: Kilian's compensation has increased whilst the company is unprofitable.


CEO

Kilian Kelly

1.3yrs

테뉴어

AU$544,827

보상

Dr. Kilian Kelly has been Chief Executive Officer and Managing Director at Cynata Therapeutics Limited since July 1, 2023 and has been its Director since 2023 and had been its Chief Operating Officer since...


리더십 팀

이름위치테뉴어보상소유권
Kilian Kelly
MD, CEO & Director1.3yrsAU$544.83k0.34%
A$ 142.5k
Jolanta Airey
Chief Medical Officer3.1yrsAU$398.72k데이터 없음
Mathias Kroll
Chief Business Officerless than a yearAU$379.02k데이터 없음
Peter Webse
Company Secretary12.6yrsAU$140.00k데이터 없음

2.2yrs

평균 재임 기간

경험이 풍부한 관리: CYP's management team is considered experienced (2.2 years average tenure).


이사회 구성원

이름위치테뉴어보상소유권
Kilian Kelly
MD, CEO & Director1.8yrsAU$544.83k0.34%
A$ 142.5k
Geoffrey Edward Brooke
Independent Non-Executive Chairman5.5yrsAU$138.77k0.14%
A$ 59.2k
Paul Wotton
Independent Non-Executive Director8.4yrsAU$68.20k0.17%
A$ 72.5k
Janine Rolfe
Independent Non-Executive Director2.2yrsAU$81.69k0.064%
A$ 26.7k
Darryl Maher
Independent Non-Executive Director4.4yrsAU$68.20k0.028%
A$ 11.5k

4.4yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: CYP's board of directors are considered experienced (4.4 years average tenure).